FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (Nasdaq: BMTI) announced today the completion of a public offering of 3,253,350 shares of its common stock, which includes 424,350 shares sold upon full exercise of the underwriters’ over-allotment options. Of the shares of common stock being offered, 2,517,111 were sold by the Company, and the remaining 736,239 shares of common stock were sold by selling stockholders identified in the prospectus. All of the shares were sold at a price of $17.15 per share. BioMimetic Therapeutics, Inc. did not receive any proceeds from the sale by the selling stockholders.
